These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 37403655)

  • 1. Similarities and distinctions between acetazolamide and sodium-glucose cotransporter 2 inhibitors in patients with acute heart failure: Key insights into ADVOR and EMPULSE.
    Packer M; Butler J
    Eur J Heart Fail; 2023 Sep; 25(9):1537-1543. PubMed ID: 37403655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial.
    Mordi NA; Mordi IR; Singh JS; Baig F; Choy AM; McCrimmon RJ; Struthers AD; Lang CC
    BMJ Open; 2017 Oct; 7(10):e018097. PubMed ID: 29042392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empagliflozin in Heart Failure: Regional Nephron Sodium Handling Effects.
    Rao VS; Ivey-Miranda JB; Cox ZL; Moreno-Villagomez J; Maulion C; Bellumkonda L; Chang J; Field MP; Wiederin DR; Butler J; Collins SP; Turner JM; Wilson FP; Inzucchi SE; Wilcox CS; Ellison DH; Testani JM
    J Am Soc Nephrol; 2024 Feb; 35(2):189-201. PubMed ID: 38073038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes.
    Packer M; Wilcox CS; Testani JM
    Circulation; 2023 Jul; 148(4):354-372. PubMed ID: 37486998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of durable natriuresis and objective decongestion following SGLT2 inhibition in randomized controlled trials of patients with heart failure.
    Packer M
    Cardiovasc Diabetol; 2023 Aug; 22(1):197. PubMed ID: 37533009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Prespecified Analysis From the ADVOR Trial.
    Martens P; Dauw J; Verbrugge FH; Nijst P; Meekers E; Augusto SN; Ter Maaten JM; Damman K; Mebazaa A; Filippatos G; Ruschitzka F; Tang WHW; Dupont M; Mullens W
    Circulation; 2023 Jan; 147(3):201-211. PubMed ID: 36335479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
    Mordi NA; Mordi IR; Singh JS; McCrimmon RJ; Struthers AD; Lang CC
    Circulation; 2020 Nov; 142(18):1713-1724. PubMed ID: 32865004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
    Packer M; Anker SD; Butler J; Filippatos G; Zannad F
    JAMA Cardiol; 2017 Sep; 2(9):1025-1029. PubMed ID: 28768320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetazolamide in Decompensated Heart Failure with Volume Overload trial (ADVOR): baseline characteristics.
    Mullens W; Dauw J; Martens P; Meekers E; Nijst P; Verbrugge FH; Chenot F; Moubayed S; Dierckx R; Blouard P; Derthoo D; Smolders W; Ector B; Hulselmans M; Lochy S; Raes D; Van Craenenbroeck E; Vandekerckhove H; Hofkens PJ; Goossens K; Pouleur AC; De Ceuninck M; Gabriel L; Timmermans P; Prihadi EA; Van Durme F; Depauw M; Vervloet D; Viaene E; Vachiery JL; Tartaglia K; Ter Maaten JM; Bruckers L; Droogne W; Troisfontaines P; Damman K; Lassus J; Mebazaa A; Filippatos G; Ruschitzka F; Dupont M
    Eur J Heart Fail; 2022 Sep; 24(9):1601-1610. PubMed ID: 35733283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-glucose Co-transporter 2 Inhibitors in Acute Heart Failure: A Review of the Available Evidence and Practical Guidance on Clinical Use.
    Morillas H; Galcerá E; Alania E; Seller J; Larumbe A; Núñez J; Valle A
    Rev Cardiovasc Med; 2022 Apr; 23(4):139. PubMed ID: 39076216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-treatment bicarbonate levels and decongestion by acetazolamide: the ADVOR trial.
    Martens P; Verbrugge FH; Dauw J; Nijst P; Meekers E; Augusto SN; Ter Maaten JM; Heylen L; Damman K; Mebazaa A; Filippatos G; Ruschitzka F; Tang WHW; Dupont M; Mullens W
    Eur Heart J; 2023 Jun; 44(22):1995-2005. PubMed ID: 37138385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-glucose cotransporter 2 inhibitors and cardiovascular clinical outcomes in acute heart failure: A narrative review.
    Rodriguez R; Kaluzna SD
    Am J Health Syst Pharm; 2023 Jun; 80(13):818-826. PubMed ID: 36971375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.
    Packer M; Anker SD; Butler J; Filippatos G; Ferreira JP; Pocock SJ; Sattar N; Brueckmann M; Jamal W; Cotton D; Iwata T; Zannad F;
    J Am Coll Cardiol; 2021 Mar; 77(11):1381-1392. PubMed ID: 33736819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal upregulation of NCC counteracts empagliflozin-mediated NHE3 inhibition in normotensive but not in hypertensive male rat.
    Castro PC; Santos-Rios TM; Martins FL; Crajoinas RO; Caetano MV; Lessa LMA; Luchi WM; McCormick JA; Girardi ACC
    Am J Physiol Cell Physiol; 2024 Jun; 326(6):C1573-C1589. PubMed ID: 38557357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial.
    Tromp J; Ponikowski P; Salsali A; Angermann CE; Biegus J; Blatchford J; Collins SP; Ferreira JP; Grauer C; Kosiborod M; Nassif ME; Psotka MA; Brueckmann M; Teerlink JR; Voors AA
    Eur J Heart Fail; 2021 May; 23(5):826-834. PubMed ID: 33609072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A role for tubular Na
    Onishi A; Fu Y; Patel R; Darshi M; Crespo-Masip M; Huang W; Song P; Freeman B; Kim YC; Soleimani M; Sharma K; Thomson SC; Vallon V
    Am J Physiol Renal Physiol; 2020 Oct; 319(4):F712-F728. PubMed ID: 32893663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis.
    Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
    Cardiovasc Diabetol; 2022 Feb; 21(1):20. PubMed ID: 35123480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tackling Congestion in Acute Heart Failure: Is It the Primetime for "Combo Diuretic Therapy?".
    Kazory A; Ronco C
    Cardiorenal Med; 2023; 13(1):184-188. PubMed ID: 36787714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF).
    Schulze PC; Bogoviku J; Westphal J; Aftanski P; Haertel F; Grund S; von Haehling S; Schumacher U; Möbius-Winkler S; Busch M
    Circulation; 2022 Jul; 146(4):289-298. PubMed ID: 35766022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial.
    Mullens W; Verbrugge FH; Nijst P; Martens P; Tartaglia K; Theunissen E; Bruckers L; Droogne W; Troisfontaines P; Damman K; Lassus J; Mebazaa A; Filippatos G; Ruschitzka F; Dupont M
    Eur J Heart Fail; 2018 Nov; 20(11):1591-1600. PubMed ID: 30238574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.